Lemborexant Safety in Late Pregnancy and Lactation
Lemborexant should be avoided during the third trimester of pregnancy due to lack of safety data, and can be used cautiously during lactation given the minimal drug transfer into breast milk (RID 1.96%).
Pregnancy (Third Trimester)
There is no available safety data for lemborexant use during pregnancy. The FDA drug label does not provide pregnancy-specific guidance 1. Following the principle established in rheumatology guidelines, drugs with insufficient safety data should be avoided during pregnancy until further evidence becomes available 2.
Key Considerations:
- No human pregnancy data exists for lemborexant
- As a small molecule dual orexin receptor antagonist, lemborexant likely crosses the placenta
- The 2020 ACR guideline explicitly states that small molecules are likely to pass through the placenta and notes no available evidence regarding safety of new small-molecule agents during pregnancy 3
- Risk-benefit assessment: Given insomnia is not life-threatening and alternative pregnancy-compatible approaches exist (behavioral interventions, certain antihistamines), the lack of safety data mandates avoidance
Lactation
Lemborexant can be considered during breastfeeding with appropriate counseling, though caution is warranted given limited data.
Evidence Supporting Use:
A 2024 pharmacokinetic study in healthy lactating women demonstrated 4:
- Relative Infant Dose (RID): 1.96% of maternal weight-adjusted dose
- Mean cumulative excretion: only 0.174% of the 10 mg maternal dose appeared in breast milk over 10 days
- Approximately 70% of excreted drug accumulated within first 24 hours
- Well below the 10% RID threshold generally considered acceptable for breastfeeding
- Drug was well-tolerated with only mild adverse events
Clinical Approach:
- The extremely low RID (1.96%) suggests minimal infant exposure
- This falls into the category of drugs with "very low levels in breast milk and no evidence of harm" similar to the framework used for other medications with limited lactation data 2
- Timing strategy: If using lemborexant, consider taking dose immediately after breastfeeding and before longest infant sleep interval to minimize exposure
- Monitor infant for excessive sedation or poor feeding
Important Caveats:
- Data is from single-dose study; chronic use patterns may differ
- Premature or ill infants may have reduced drug clearance
- Consider non-pharmacologic interventions first (sleep hygiene, cognitive behavioral therapy for insomnia)
- If insomnia is severe and impacting maternal function/safety, the low RID supports use over untreated maternal sleep deprivation
The contrast between pregnancy and lactation recommendations reflects the fundamental difference: in pregnancy, the drug likely crosses to the fetus with unknown effects, while in lactation, quantifiable minimal transfer (1.96% RID) provides reassurance of safety 4.